Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2018

Open Access 01-12-2018 | Research article

A modified M-stage classification based on the metastatic patterns of pancreatic neuroendocrine neoplasms: a population-based study

Authors: Xianbin Zhang, Jiaxin Song, Peng Liu, Mohammad Abdul Mazid, Lili Lu, Yuru Shang, Yushan Wei, Peng Gong, Li Ma

Published in: BMC Endocrine Disorders | Issue 1/2018

Login to get access

Abstract

Background

The present study aims to improve the M-stage classification of pancreatic neuroendocrine neoplasms (pNENs).

Methods

Two thousand six hundred sixty six pNENs were extracted from the Surveillance, Epidemiology, and End Results database to explore the metastatic patterns of pNENs. Metastatic patterns were categorized as single, two, or multiple (three or more) distant organ metastasis. The mean overall survival and hazard rate of different metastatic patterns were calculated by Kaplan-Meier and Cox proportional hazards models, respectively. The discriminatory capability of the modified M-stage classification was evaluated by Harrell’s concordance index.

Results

The overall survival time significantly decreased with an increasing number of metastatic organs. In addition, pNENs with only liver metastasis had better prognosis when compared to other metastatic patterns. Thus, we modified the M-stage classification (mM-stage) as follows: mM0-stage, tumor without metastasis; mM1-stage, tumor only metastasized to liver; mM2-stage, tumor metastasized to other single distant organ (lung, bone, or brain) or two distant organs; mM3-stage, tumor metastasized to three or more distant organs. Harrell’s concordance index showed that the modified M-stage classification had superior discriminatory capability than both the American Joint Committee on Cancer (AJCC) and the European Neuroendocrine Tumor Society (ENETS) M-stage classifications.

Conclusions

The modified M-stage classification is superior to both AJCC and ENETS M-stage classifications in the prognosis of pNENs. In the future, individualized treatment and follow-up programs should be explored for patients with distinct metastatic patterns.
Appendix
Available only for authorised users
Literature
1.
go back to reference Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRef Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.CrossRef
2.
go back to reference Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7.CrossRef Panzuto F, Boninsegna L, Fazio N, et al. Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol. 2011;29:2372–7.CrossRef
3.
go back to reference Zhang X, Lu L, Shang Y, et al. The number of positive lymph node is a better predictor of survival than the lymph node metastasis status for pancreatic neuroendocrine neoplasms: a retrospective cohort study. Int J Surg. 2017;48:142–8.CrossRef Zhang X, Lu L, Shang Y, et al. The number of positive lymph node is a better predictor of survival than the lymph node metastasis status for pancreatic neuroendocrine neoplasms: a retrospective cohort study. Int J Surg. 2017;48:142–8.CrossRef
4.
go back to reference Jin K, Xu J, Chen J, et al. Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: a consensus from the Chinese study Group for Neuroendocrine Tumors (CSNET). Int J Oncol. 2016;49:1991–2000.CrossRef Jin K, Xu J, Chen J, et al. Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: a consensus from the Chinese study Group for Neuroendocrine Tumors (CSNET). Int J Oncol. 2016;49:1991–2000.CrossRef
5.
go back to reference Garcia-Carbonero R, Rinke A, Valle JW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. 2017;105:281–94.CrossRef Garcia-Carbonero R, Rinke A, Valle JW, et al. ENETS consensus guidelines for the standards of care in neuroendocrine neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. 2017;105:281–94.CrossRef
6.
go back to reference Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? Am Coll Surg. 2000;190:432–45.CrossRef Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? Am Coll Surg. 2000;190:432–45.CrossRef
7.
go back to reference Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21:11767–76.CrossRef Vatandoust S, Price TJ, Karapetis CS. Colorectal cancer: metastases to a single organ. World J Gastroenterol. 2015;21:11767–76.CrossRef
8.
go back to reference Bando E, Makuuchi R, Tokunaga M, et al. Impact of clinical tumor–node–metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer. 2017;20:448–56.CrossRef Bando E, Makuuchi R, Tokunaga M, et al. Impact of clinical tumor–node–metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer. 2017;20:448–56.CrossRef
9.
go back to reference Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European neuroendocrine tumour society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18.CrossRef Niederle MB, Hackl M, Kaserer K, et al. Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European neuroendocrine tumour society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer. 2010;17:909–18.CrossRef
10.
go back to reference Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1–18.CrossRef Lawrence B, Gustafsson BI, Chan A, et al. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am. 2011;40:1–18.CrossRef
11.
go back to reference Pavel M, Costa F, Capdevila J, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.CrossRef Pavel M, Costa F, Capdevila J, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.CrossRef
12.
go back to reference Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150:195–203.CrossRef Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol. 1986;150:195–203.CrossRef
13.
go back to reference Partelli S, Bartsch DK, Capdevila J, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105:255–65.CrossRef Partelli S, Bartsch DK, Capdevila J, et al. ENETS consensus guidelines for standard of care in neuroendocrine tumours: surgery for small intestinal and pancreatic neuroendocrine tumours. Neuroendocrinology. 2017;105:255–65.CrossRef
14.
go back to reference Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Onco. 2015;22:1000–7.CrossRef Birnbaum DJ, Turrini O, Vigano L, et al. Surgical management of advanced pancreatic neuroendocrine tumors: short-term and long-term results from an international multi-institutional study. Ann Surg Onco. 2015;22:1000–7.CrossRef
15.
go back to reference S D LW, GY B, et al. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. World J Surg Oncol. 2017;15:120.CrossRef S D LW, GY B, et al. Risk factors of liver metastasis from advanced pancreatic adenocarcinoma: a large multicenter cohort study. World J Surg Oncol. 2017;15:120.CrossRef
16.
go back to reference Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485–92.PubMed Freelove R, Walling AD. Pancreatic cancer: diagnosis and management. Am Fam Physician. 2006;73:485–92.PubMed
17.
go back to reference Zhang X, Ma L, Bao H, et al. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord. 2014;14:54.CrossRef Zhang X, Ma L, Bao H, et al. Clinical, pathological and prognostic characteristics of gastroenteropancreatic neuroendocrine neoplasms in China: a retrospective study. BMC Endocr Disord. 2014;14:54.CrossRef
18.
go back to reference Hlatky R, Suki D, Sawaya R. Carcinoid metastasis to the brain. Cancer. 2004;101:2605–13.CrossRef Hlatky R, Suki D, Sawaya R. Carcinoid metastasis to the brain. Cancer. 2004;101:2605–13.CrossRef
Metadata
Title
A modified M-stage classification based on the metastatic patterns of pancreatic neuroendocrine neoplasms: a population-based study
Authors
Xianbin Zhang
Jiaxin Song
Peng Liu
Mohammad Abdul Mazid
Lili Lu
Yuru Shang
Yushan Wei
Peng Gong
Li Ma
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2018
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-018-0301-z

Other articles of this Issue 1/2018

BMC Endocrine Disorders 1/2018 Go to the issue